Ollin Biosciences, Inc.
Clinical trials sponsored by Ollin Biosciences, Inc., explained in plain language.
-
New eye drug goes Head-to-Head with standard treatment for wet AMD
Disease control Not yet recruitingResearchers are testing an experimental drug called OLN324 against ranibizumab, a standard treatment for wet age-related macular degeneration (nAMD). The trial enrolls about 400 adults aged 50 and older who have not yet received treatment for active wet AMD in the study eye. Part…
Phase 3 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New eye drug goes Head-to-Head with standard care for wet AMD
Disease control Not yet recruitingResearchers are testing an experimental drug called OLN324 against the standard treatment, aflibercept, in adults with wet age-related macular degeneration. About 500 people aged 50 and older who have not yet received treatment for this condition will take part. Both drugs are gi…
Phase 3 • Sponsor: Ollin Biosciences, Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC